Cargando…

Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer – a first clinical approach

BACKGROUND: Expression of CXCR4, a chemokine (C-X-C motif) receptor that plays a central role in tumor growth and metastasis of circulating tumor cells, has been described in a variety of solid tumors. A high expression of CXCR4 has a prognostic significance with regard to overall and progression-fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linde, Philipp, Baues, Christian, Wegen, Simone, Trommer, Maike, Quaas, Alexander, Rosenbrock, Johannes, Celik, Eren, Marnitz, Simone, Bruns, Christiane J., Fischer, Thomas, Schomaecker, Klaus, Wester, Hans-Juergen, Drzezga, Alexander, van Heek, Lutz, Kobe, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881561/ https://www.ncbi.nlm.nih.gov/pubmed/33579381 http://dx.doi.org/10.1186/s40644-021-00391-w

Ejemplares similares

Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis
por: Linde, Philipp, et al.
Publicado: (2022)

The Role of Age and Comorbidities in Esophagogastric Cancer Chemoradiation of the Frail Elderly (>70 Years): An Analysis from a Tertiary High Volume-Center
por: Linde, Philipp, et al.
Publicado: (2022)

First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
por: Wegen, Simone, et al.
Publicado: (2023)

Head-to-Head Comparison of [(68) Ga]Ga-FAPI-46-PET/CT and [(18)F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
por: Wegen, Simone, et al.
Publicado: (2022)

Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients – An Analysis of GHSG HD14- and HD17-Patients
por: Rosenbrock, Johannes, et al.
Publicado: (2021)

Teaching in radiation oncology: now and 2025—results of a focus group with medical students
por: Linde, Philipp, et al.
Publicado: (2022)

Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching
por: Trommer, Maike, et al.
Publicado: (2020)

Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
por: Rosenbrock, Johannes, et al.
Publicado: (2023)

Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups
por: Trommer, Maike, et al.
Publicado: (2022)

[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques
por: Li, Xiang, et al.
Publicado: (2017)

Managing patient flows in radiation oncology during the COVID-19 pandemic: Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital
por: Akuamoa-Boateng, Dennis, et al.
Publicado: (2020)

Correction to: Managing patient flows in radiation oncology during the COVID-19 pandemic: Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital
por: Akuamoa-Boateng, Dennis, et al.
Publicado: (2020)

[(68)Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery
por: Li, Xiang, et al.
Publicado: (2019)

Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment
por: Trommer-Nestler, Maike, et al.
Publicado: (2018)

Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer
por: Morgenthaler, Janis, et al.
Publicado: (2020)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2019)

Corrigendum: Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2020)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
por: Hammes, Jochen, et al.
Publicado: (2018)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer
por: Celik, Eren, et al.
Publicado: (2020)

The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

COVID-19 und die Onkologie: agiles Patientenmanagement: Reorganisation der radioonkologischen Versorgung am Universitätsklinikum Köln
por: Akuamoa-Boateng, Dennis, et al.
Publicado: (2022)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
por: Tsakmaklis, Anastasia, et al.
Publicado: (2020)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients
por: Lewis, Richard, et al.
Publicado: (2021)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI
por: Haug, Alexander R., et al.
Publicado: (2019)

Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [(68)Ga]pentixafor PET/CT
por: Derlin, Thorsten, et al.
Publicado: (2018)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

Synthesis, validation and quality controls of [(68)Ga]-DOTA-Pentixafor for PET imaging of chemokine receptor CXCR4 expression
por: Sammartano, Antonino, et al.
Publicado: (2020)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

Semi-quantitative measurements of chemokine receptor 4-targeted (68)Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
por: Pan, Qingqing, et al.
Publicado: (2021)

32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES
por: Galldiks, Norbert, et al.
Publicado: (2020)

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [(68)Ga]pentixafor in non-Hodgkin lymphoma: comparison to [(18)F]FDG
por: Pan, Qingqing, et al.
Publicado: (2020)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lrk0q4hg746l484okhd9tceod5